ID   NCI-H3122-CR1
AC   CVCL_AY53
AS   CVCL_VJ82
SY   NCI-H3122 CR1; H3122 CR1
DR   Cosmic; 1860358
DR   Wikidata; Q54872053
RX   PubMed=21502504;
RX   PubMed=23344087;
RX   PubMed=24675041;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:64310; Crizotinib (Xalkori).
CC   Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5160 ! NCI-H3122
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 02-05-16; Last updated: 05-10-23; Version: 8
//
RX   PubMed=21502504; DOI=10.1073/pnas.1019559108;
RA   Katayama R., Khan T.M., Benes C., Lifshits E., Ebi H., Rivera V.M.,
RA   Shakespeare W.C., Iafrate A.J., Engelman J.A., Shaw A.T.;
RT   "Therapeutic strategies to overcome crizotinib resistance in non-small
RT   cell lung cancers harboring the fusion oncogene EML4-ALK.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:7535-7540(2011).
//
RX   PubMed=23344087; DOI=10.1097/JTO.0b013e318283dcc0;
RA   Kim S., Kim T.M., Kim D.-W., Go H., Keam B., Lee S.-H., Ku J.-L.,
RA   Chung D.H., Heo D.S.;
RT   "Heterogeneity of genetic changes associated with acquired crizotinib
RT   resistance in ALK-rearranged lung cancer.";
RL   J. Thorac. Oncol. 8:415-422(2013).
//
RX   PubMed=24675041; DOI=10.1158/2159-8290.CD-13-0846;
RA   Friboulet L., Li N.-X., Katayama R., Lee C.C., Gainor J.F., Crystal A.S.,
RA   Michellys P.-Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C.,
RA   Li J., Kasibhatla S., Sun F., Sun X.-Y., Hua S., McNamara P., Mahmood S.,
RA   Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T.,
RA   Engelman J.A.;
RT   "The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small
RT   cell lung cancer.";
RL   Cancer Discov. 4:662-673(2014).
//